Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential (NASDAQ:ARWR)

Single strand ribonucleic acid, RNA research

luismmolina

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a clinical-stage biotechnology company with a wide pipeline of potential RNAi therapies. It is getting into the home stretch now, with three Phase 3 trials in progress, plus three each of Phase 1 and Phase 2 trials, and several

Read more here: Source link